OVIDOvid Therapeutics Inc.

Nasdaq ovidrx.com


$ 1.00 $ 0.04 (4.43 %)    

Friday, 19-Jul-2024 11:40:55 EDT
QQQ $ 477.37 $ -3.14 (-0.65 %)
DIA $ 403.56 $ -1.87 (-0.46 %)
SPY $ 551.02 $ -1.35 (-0.25 %)
TLT $ 93.03 $ -0.01 (-0.02 %)
GLD $ 222.24 $ 0.79 (0.36 %)
$ 0.9576
$ 0.97
$ 0.99 x 200
$ 1.01 x 200
$ 0.97 - $ 1.00
$ 0.68 - $ 4.14
377,706
na
67.72M
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-08-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 03-13-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-11-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 03-07-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-29-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 06-13-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ovid-therapeutics-announces-eneuro-publishes-findings-on-the-anti-convulsant-properties-of-ov329-and-its-potential-effectiveness-in-treatment-resistant-seizures

Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA...

 hc-wainwright--co-reiterates-buy-on-ovid-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $3 pr...

 ovid-therapeutics-and-graviton-bioscience-announces-topline-data-from-phase-1-clinical-trial-studying-ov888gv101-capsule-for-cerebral-cavernous-malformations

The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no ...

 btig-maintains-buy-on-ovid-therapeutics-lowers-price-target-to-5

BTIG analyst Thomas Shrader maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $11 to $5.

 b-riley-securities-maintains-buy-on-ovid-therapeutics-lowers-price-target-to-3

B. Riley Securities analyst Kalpit Patel maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target fr...

 citigroup-maintains-neutral-on-ovid-therapeutics-lowers-price-target-to-12

Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target fro...

 hc-wainwright--co-maintains-buy-on-ovid-therapeutics-lowers-price-target-to-3

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price...

 whats-going-on-with-ovid-therapeutics-after-takedas-two-phase-3-epilepsy-studies-fail

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In ...

Core News & Articles

SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed ...

 hc-wainwright--co-reiterates-buy-on-ovid-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $9 pr...

 ovid-therapeutics-q1-eps-017-beats-021-estimate-sales-14800k-beat-5000k-estimate

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0...